{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:33:08Z","timestamp":1789320788277,"version":"build-2803163510"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"university level scientific research project of Zhejiang Shuren University","award":["2022R005"],"award-info":[{"award-number":["2022R005"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874302"],"award-info":[{"award-number":["81874302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rheumatoid arthritis (RA) is a systemic immune disease characterized by synovial inflammation. Patients with RA commonly experience significant damage to their hand and foot joints, which can lead to joint deformities and even disability. Traditional treatments have several clinical drawbacks, including unclear pharmacological mechanisms and serious side effects. However, the emergence of antibody drugs offers a promising approach to overcome these limitations by specifically targeting interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-\u03b1), and other cytokines that are closely related to the onset of RA. This approach reduces the incidence of adverse effects and contributes to significant therapeutic outcomes. Furthermore, combining these antibody drugs with drug delivery nanosystems (DDSs) can improve their tissue accumulation and bioavailability.Herein, we provide a summary of the pathogenesis of RA, the available antibody drugs and DDSs that improve the efficacy of these drugs. However, several challenges need to be addressed in their clinical applications, including patient compliance, stability, immunogenicity, immunosupression, target and synergistic effects. We propose strategies to overcome these limitations. In summary, we are optimistic about the prospects of treating RA with antibody drugs, given their specific targeting mechanisms and the potential benefits of combining them with DDSs.<\/jats:p>","DOI":"10.1186\/s12951-023-01857-8","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T23:02:59Z","timestamp":1679698979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiao-Kai","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Zhong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,25]]},"reference":[{"key":"1857_CR1","doi-asserted-by":"publisher","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","volume":"12","author":"S Shams","year":"2021","unstructured":"Shams S, Martinez JM, Dawson JRD, et al. The Therapeutic Landscape of Rheumatoid Arthritis: current state and future directions. Front Pharmacol. 2021;12:680043. https:\/\/doi.org\/10.3389\/fphar.2021.680043. Published 2021 May 28.","journal-title":"Front Pharmacol"},{"issue":"10086","key":"1857_CR2","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(17)31472-1","journal-title":"Lancet"},{"issue":"13","key":"1857_CR3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"1857_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.biopha.2017.05.055","volume":"92","author":"J Alam","year":"2017","unstructured":"Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017;92:615\u201333. https:\/\/doi.org\/10.1016\/j.biopha.2017.05.055","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1857_CR5","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.apsb.2021.03.013","volume":"11","author":"Q Wang","year":"2021","unstructured":"Wang Q, Qin X, Fang J, Sun X. Nanomedicines for the treatment of rheumatoid arthritis: state of art and potential therapeutic strategies. Acta Pharm Sin B. 2021;11(5):1158\u201374. https:\/\/doi.org\/10.1016\/j.apsb.2021.03.013","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"1857_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/art.40398","volume":"70","author":"Y Kondo","year":"2018","unstructured":"Kondo Y, Yokosawa M, Kaneko S, et al. Review: transcriptional regulation of CD4 + T-Cell differentiation in experimentally Induced Arthritis and Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70(5):653\u201361. https:\/\/doi.org\/10.1002\/art.40398","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1857_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14397595.2017.1386837","volume":"28","author":"Y Matsuo","year":"2018","unstructured":"Matsuo Y, Saito T, Yamamoto A, Kohsaka H. Origins of fibroblasts in rheumatoid synovial tissues: implications from organ fibrotic models. Mod Rheumatol. 2018;28(4):579\u201382. https:\/\/doi.org\/10.1080\/14397595.2017.1386837","journal-title":"Mod Rheumatol"},{"key":"1857_CR8","doi-asserted-by":"publisher","unstructured":"Chuang SY, Lin CH, Huang TH, Fang JY. Lipid-Based Nanoparticles as a Potential Delivery Approach in the Treatment of Rheumatoid Arthritis. Nanomaterials (Basel). 2018;8(1):42. Published 2018 Jan 15. doi:https:\/\/doi.org\/10.3390\/nano8010042","DOI":"10.3390\/nano8010042"},{"issue":"27","key":"1857_CR9","doi-asserted-by":"publisher","first-page":"e2202604","DOI":"10.1002\/smll.202202604","volume":"18","author":"L Guo","year":"2022","unstructured":"Guo L, Zhong S, Liu P, Guo M, Ding J, Zhou W. Radicals scavenging MOFs enabling targeting delivery of siRNA for rheumatoid arthritis therapy. Small. 2022;18(27):e2202604. https:\/\/doi.org\/10.1002\/smll.202202604","journal-title":"Small"},{"key":"1857_CR10","doi-asserted-by":"publisher","first-page":"120390","DOI":"10.1016\/j.biomaterials.2020.120390","volume":"264","author":"Y Yang","year":"2021","unstructured":"Yang Y, Guo L, Wang Z, et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and repolarization. Biomaterials. 2021;264:120390. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120390","journal-title":"Biomaterials"},{"key":"1857_CR11","doi-asserted-by":"publisher","unstructured":"Chen SJ, Lin GJ, Chen JW et al. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis. Int J Mol Sci. 2019;20(6):1332. Published 2019 Mar 16. doi:https:\/\/doi.org\/10.3390\/ijms20061332","DOI":"10.3390\/ijms20061332"},{"issue":"5","key":"1857_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/ijms18050905","volume":"18","author":"Y Araki","year":"2017","unstructured":"Araki Y, Mimura T. Matrix Metalloproteinase Gene Activation resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. Int J Mol Sci. 2017;18(5):905. https:\/\/doi.org\/10.3390\/ijms18050905. Published 2017 Apr 25.","journal-title":"Int J Mol Sci"},{"key":"1857_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bcp.2019.02.020","volume":"165","author":"M Arioka","year":"2019","unstructured":"Arioka M, Takahashi-Yanaga F. Glycogen synthase kinase-3 inhibitor as a multitargeting anti-rheumatoid drug. Biochem Pharmacol. 2019;165:207\u201313. https:\/\/doi.org\/10.1016\/j.bcp.2019.02.020","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1857_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14397595.2017.1369491","volume":"28","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, Takeuchi T. RANKL: a therapeutic target for bone destruction in rheumatoid arthritis. Mod Rheumatol. 2018;28(1):9\u201316. https:\/\/doi.org\/10.1080\/14397595.2017.1369491","journal-title":"Mod Rheumatol"},{"issue":"5","key":"1857_CR15","doi-asserted-by":"publisher","first-page":"101482","DOI":"10.1016\/j.berh.2019.101482","volume":"33","author":"AA K\u00fc\u00e7\u00fckdeveci","year":"2019","unstructured":"K\u00fc\u00e7\u00fckdeveci AA. Nonpharmacological treatment in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019;33(5):101482. https:\/\/doi.org\/10.1016\/j.berh.2019.101482","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"1857_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/jcm8070938","volume":"8","author":"BM K\u00f6hler","year":"2019","unstructured":"K\u00f6hler BM, G\u00fcnther J, Kaudewitz D, Lorenz HM. Current therapeutic options in the treatment of rheumatoid arthritis. J Clin Med. 2019;8(7):938. https:\/\/doi.org\/10.3390\/jcm8070938. Published 2019 Jun 28.","journal-title":"J Clin Med"},{"issue":"2","key":"1857_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1381612825666190321104424","volume":"25","author":"XL Xu","year":"2019","unstructured":"Xu XL, Lu KJ, Yao XQ, Ying XY, Du YZ. Stimuli-responsive drug Delivery Systems as an emerging platform for treatment of rheumatoid arthritis. Curr Pharm Des. 2019;25(2):155\u201365. https:\/\/doi.org\/10.2174\/1381612825666190321104424","journal-title":"Curr Pharm Des"},{"issue":"5","key":"1857_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s41061-019-0252-5","volume":"377","author":"S Zhou","year":"2019","unstructured":"Zhou S, Zou H, Chen G, Huang G. Synthesis and Biological Activities of Chemical drugs for the treatment of rheumatoid arthritis. Top Curr Chem (Cham). 2019;377(5):28. https:\/\/doi.org\/10.1007\/s41061-019-0252-5. Published 2019 Sep 28.","journal-title":"Top Curr Chem (Cham)"},{"key":"1857_CR19","doi-asserted-by":"publisher","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J et al. Methotrexate an Old Drug with New Tricks. Int J Mol Sci. 2019;20(20):5023. Published 2019 Oct 10. doi:https:\/\/doi.org\/10.3390\/ijms20205023","DOI":"10.3390\/ijms20205023"},{"key":"1857_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jconrel.2020.10.069","volume":"330","author":"L Guo","year":"2021","unstructured":"Guo L, Chen Y, Wang T, et al. Rational design of metal-organic frameworks to deliver methotrexate for targeted rheumatoid arthritis therapy. J Control Release. 2021;330:119\u201331. https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.069","journal-title":"J Control Release"},{"issue":"3","key":"1857_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/10408347.2018.1503943","volume":"49","author":"A Dogra","year":"2019","unstructured":"Dogra A, Sharma A, Kumar Mandal U, Kotwal P, Bhatt S, Nandi U. Liquid chromatography based methods for analysis of Disease-Modifying antirheumatic drugs (DMARDs) in Biological Matrices. Crit Rev Anal Chem. 2019;49(3):224\u201342. https:\/\/doi.org\/10.1080\/10408347.2018.1503943","journal-title":"Crit Rev Anal Chem"},{"issue":"2","key":"1857_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.semarthrit.2019.07.012","volume":"50","author":"J Braun","year":"2020","unstructured":"Braun J, Baraliakos X, Westhoff T. Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication. Semin Arthritis Rheum. 2020;50(2):285\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.07.012","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1857_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","volume":"16","author":"F Buttgereit","year":"2020","unstructured":"Buttgereit F. Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol. 2020;16(4):239\u201346. https:\/\/doi.org\/10.1038\/s41584-020-0370-z","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1857_CR24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","volume":"11","author":"Q Xiao","year":"2021","unstructured":"Xiao Q, Li X, Li Y, et al. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021;11(4):941\u201360. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.018","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"1857_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3831\/KPI.2019.22.029","volume":"22","author":"D Kesharwani","year":"2019","unstructured":"Kesharwani D, Paliwal R, Satapathy T, Das Paul S. Rheumatiod Arthritis: an updated overview of latest therapy and drug delivery. J Pharmacopunct. 2019;22(4):210\u201324. https:\/\/doi.org\/10.3831\/KPI.2019.22.029","journal-title":"J Pharmacopunct"},{"issue":"5","key":"1857_CR26","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"DI Jang","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, et al. The role of Tumor necrosis factor alpha (TNF-\u03b1) in Autoimmune Disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719. https:\/\/doi.org\/10.3390\/ijms22052719. Published 2021 Mar 8.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1857_CR27","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Sch\u00fclke S. Update on the Pathomechanism, diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells. 2020;9(4):880. https:\/\/doi.org\/10.3390\/cells9040880. Published 2020 Apr 3.","journal-title":"Cells"},{"key":"1857_CR28","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3389\/fimmu.2019.02925","volume":"10","author":"A Marahleh","year":"2019","unstructured":"Marahleh A, Kitaura H, Ohori F, et al. TNF-\u03b1 directly enhances osteocyte RANKL expression and promotes osteoclast formation. Front Immunol. 2019;10:2925. https:\/\/doi.org\/10.3389\/fimmu.2019.02925. Published 2019 Dec 13.","journal-title":"Front Immunol"},{"key":"1857_CR29","doi-asserted-by":"publisher","unstructured":"Lim H, Lee SH, Lee HT et al. Structural Biology of the TNF\u03b1 Antagonists Used in the Treatment of Rheumatoid Arthritis. Int J Mol Sci. 2018;19(3):768. Published 2018 Mar 7. doi:https:\/\/doi.org\/10.3390\/ijms19030768","DOI":"10.3390\/ijms19030768"},{"issue":"7","key":"1857_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/jcm8070938","volume":"8","author":"BM K\u00f6hler","year":"2019","unstructured":"K\u00f6hler BM, G\u00fcnther J, Kaudewitz D, Lorenz HM. Current therapeutic options in the treatment of rheumatoid arthritis. J Clin Med. 2019;8(7):938. https:\/\/doi.org\/10.3390\/jcm8070938. Published 2019 Jun 28.","journal-title":"J Clin Med"},{"issue":"6","key":"1857_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/imt-2017-0155","volume":"10","author":"S Zhao","year":"2018","unstructured":"Zhao S, Mysler E, Moots RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018;10(6):433\u201345. https:\/\/doi.org\/10.2217\/imt-2017-0155","journal-title":"Immunotherapy"},{"key":"1857_CR32","doi-asserted-by":"publisher","unstructured":"Chen SJ, Lin GJ, Chen JW et al. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis. Int J Mol Sci. 2019;20(6):1332. Published 2019 Mar 16. doi:https:\/\/doi.org\/10.3390\/ijms20061332","DOI":"10.3390\/ijms20061332"},{"issue":"9","key":"1857_CR33","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/annrheumdis-2018-214860","volume":"78","author":"T Dervieux","year":"2019","unstructured":"Dervieux T, Kremer JM, Weinblatt ME. Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Ann Rheum Dis. 2019;78(9):1285\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214860","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1857_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717\u201322. https:\/\/doi.org\/10.1086\/506935","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1857_CR35","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1002\/jcp.27860","volume":"234","author":"M Abbasi","year":"2019","unstructured":"Abbasi M, Mousavi MJ, Jamalzehi S, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;234(7):10018\u201331. https:\/\/doi.org\/10.1002\/jcp.27860","journal-title":"J Cell Physiol"},{"issue":"1","key":"1857_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5588\/ijtld.15.0283","volume":"20","author":"A Watanabe","year":"2016","unstructured":"Watanabe A, Matsumoto T, Igari H, Sawa J, Yamaguchi Y, Sakatani M. Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan. Int J Tuberc Lung Dis. 2016;20(1):101\u20138. https:\/\/doi.org\/10.5588\/ijtld.15.0283","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"1857_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40259-016-0197-y","volume":"30","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. BioDrugs. 2016;30(6):607\u201317. https:\/\/doi.org\/10.1007\/s40259-016-0197-y","journal-title":"BioDrugs"},{"issue":"1","key":"1857_CR38","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5(1):e000942. https:\/\/doi.org\/10.1136\/rmdopen-2019-000942. Published 2019 May 31.","journal-title":"RMD Open"},{"issue":"3","key":"1857_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/jcm8030387","volume":"8","author":"E Pelechas","year":"2019","unstructured":"Pelechas E, Voulgari PV, Drosos AA. Golimumab for Rheumatoid Arthritis. J Clin Med. 2019;8(3):387. https:\/\/doi.org\/10.3390\/jcm8030387. Published 2019 Mar 20.","journal-title":"J Clin Med"},{"key":"1857_CR40","doi-asserted-by":"publisher","unstructured":"Singh S, Facciorusso A, Singh AG et al. Obesity and response to antitumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis [published correction appears in PLoS One. 2018 Aug 29;13(8):e0203499]. PLoS One. 2018;13(5):e0195123. Published 2018 May 17. doi:https:\/\/doi.org\/10.1371\/journal.pone.0195123","DOI":"10.1371\/journal.pone.0195123"},{"issue":"17","key":"1857_CR41","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1042\/CS20170098","volume":"131","author":"I Striz","year":"2017","unstructured":"Striz I. Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations. Clin Sci (Lond). 2017;131(17):2241\u201356. https:\/\/doi.org\/10.1042\/CS20170098. Published 2017 Aug 10.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"1857_CR42","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","volume":"50","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50(4):778\u201395. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.012","journal-title":"Immunity"},{"issue":"7","key":"1857_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","volume":"17","author":"J Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez J, Ca\u00f1ete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018;17(7):727\u201332. https:\/\/doi.org\/10.1080\/14740338.2018.1486819","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1857_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.semarthrit.2016.09.003","volume":"46","author":"S Tarp","year":"2017","unstructured":"Tarp S, Furst DE, Dossing A, et al. Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomized trials. Semin Arthritis Rheum. 2017;46(6):699\u2013708. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.003","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1857_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.tcm.2020.04.006","volume":"31","author":"G Lopalco","year":"2021","unstructured":"Lopalco G, Rigante D, Cantarini L, et al. The autoinflammatory side of recurrent pericarditis: enlightening the pathogenesis for a more rational treatment. Trends Cardiovasc Med. 2021;31(5):265\u201374. https:\/\/doi.org\/10.1016\/j.tcm.2020.04.006","journal-title":"Trends Cardiovasc Med"},{"key":"1857_CR46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.amjcard.2020.03.041","volume":"127","author":"M Khayata","year":"2020","unstructured":"Khayata M, Shah NP, Verma BR, et al. Usefulness of Interleukin-1 receptor antagonists in patients with recurrent Pericarditis. Am J Cardiol. 2020;127:184\u201390. https:\/\/doi.org\/10.1016\/j.amjcard.2020.03.041","journal-title":"Am J Cardiol"},{"issue":"Suppl 6","key":"1857_CR47","doi-asserted-by":"publisher","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","volume":"58","author":"SJ Vastert","year":"2019","unstructured":"Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with still\u2019s disease. Rheumatology (Oxford). 2019;58(Suppl 6):vi9\u2013vi22. https:\/\/doi.org\/10.1093\/rheumatology\/kez350","journal-title":"Rheumatology (Oxford)"},{"key":"1857_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/TCRM.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H. Biological therapy of traditional therapy-resistant adult-onset still\u2019s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167\u201371. https:\/\/doi.org\/10.2147\/TCRM.S155488. Published 2018 Jan 24.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"1857_CR49","doi-asserted-by":"publisher","first-page":"e001662","DOI":"10.1136\/rmdopen-2021-001662","volume":"7","author":"K Chatzidionysiou","year":"2021","unstructured":"Chatzidionysiou K, Circiumaru A, Rethi B, et al. Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL. RMD Open. 2021;7(2):e001662. https:\/\/doi.org\/10.1136\/rmdopen-2021-001662","journal-title":"RMD Open"},{"issue":"7","key":"1857_CR50","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","volume":"8","author":"JE Fonseca","year":"2009","unstructured":"Fonseca JE, Santos MJ, Canh\u00e3o H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538\u201342. https:\/\/doi.org\/10.1016\/j.autrev.2009.01.012","journal-title":"Autoimmun Rev"},{"key":"1857_CR51","doi-asserted-by":"publisher","unstructured":"Scott LJ, Tocilizumab. A Review in Rheumatoid Arthritis [published correction appears in Drugs. 2017 Dec 19;:]. Drugs. 2017;77(17):1865\u20131879. doi:https:\/\/doi.org\/10.1007\/s40265-017-0829-7","DOI":"10.1007\/s40265-017-0829-7"},{"key":"1857_CR52","doi-asserted-by":"publisher","unstructured":"Cappelli LC, Palmer JL, Kremer J, Bingham CO 3. Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. Semin Arthritis Rheum. 2017;47(2):165\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.024","DOI":"10.1016\/j.semarthrit.2017.03.024"},{"issue":"10","key":"1857_CR53","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/rheumatology\/kex238","volume":"56","author":"J Morel","year":"2017","unstructured":"Morel J, Constantin A, Baron G, et al. Risk factors for serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford). 2017;56(10):1746\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/kex238","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1857_CR54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","volume":"48","author":"SC Kim","year":"2018","unstructured":"Kim SC, Solomon DH, Rogers JR, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multidatabase cohort study. Semin Arthritis Rheum. 2018;48(3):399\u2013405. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.012","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1857_CR55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","volume":"29","author":"A Ogata","year":"2019","unstructured":"Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29(2):258\u201367. https:\/\/doi.org\/10.1080\/14397595.2018.1546357","journal-title":"Mod Rheumatol"},{"issue":"2","key":"1857_CR56","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/1756-185X.12686","volume":"20","author":"A Ahmadzadeh","year":"2017","unstructured":"Ahmadzadeh A, Farahmand AN, Gachkar L. Evaluation of safety, efficacy and postcessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis. Int J Rheum Dis. 2017;20(2):231\u20137. https:\/\/doi.org\/10.1111\/1756-185X.12686","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"1857_CR57","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40265-018-0929-z","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN, Deeks ED, Sarilumab. A review in moderate to severe rheumatoid arthritis. Drugs. 2018;78(9):929\u201340. https:\/\/doi.org\/10.1007\/s40265-018-0929-z","journal-title":"Drugs"},{"key":"1857_CR58","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/DDDT.S100302","volume":"11","author":"MG Raimondo","year":"2017","unstructured":"Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593\u2013603. https:\/\/doi.org\/10.2147\/DDDT.S100302. Published 2017 May 24.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"1857_CR59","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/1744666X.2017.1351297","volume":"13","author":"AM Aly","year":"2017","unstructured":"Aly AM, Furst DE. Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review. Expert Rev Clin Immunol. 2017;13(8):741\u201352. https:\/\/doi.org\/10.1080\/1744666X.2017.1351297","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"1857_CR60","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/14712598.2016.1217988","volume":"16","author":"RR June","year":"2016","unstructured":"June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303\u20139. https:\/\/doi.org\/10.1080\/14712598.2016.1217988","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"1857_CR61","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40265-017-0724-2","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ, Sarilumab. First Global approval. Drugs. 2017;77(6):705\u201312. https:\/\/doi.org\/10.1007\/s40265-017-0724-2","journal-title":"Drugs"},{"issue":"3","key":"1857_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1759720X17752037","volume":"10","author":"D McCarty","year":"2018","unstructured":"McCarty D, Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(3):61\u20137. https:\/\/doi.org\/10.1177\/1759720X17752037","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1857_CR63","doi-asserted-by":"publisher","first-page":"104402","DOI":"10.1016\/j.phrs.2019.104402","volume":"149","author":"F Atzeni","year":"2019","unstructured":"Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149:104402. https:\/\/doi.org\/10.1016\/j.phrs.2019.104402","journal-title":"Pharmacol Res"},{"issue":"4","key":"1857_CR64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","volume":"15","author":"M Pombo-Suarez","year":"2019","unstructured":"Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(4):319\u201326. https:\/\/doi.org\/10.1080\/1744666X.2019.1579642","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"1857_CR65","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED, Abatacept. A review in rheumatoid arthritis. Drugs. 2017;77(11):1221\u201333. https:\/\/doi.org\/10.1007\/s40265-017-0775-4","journal-title":"Drugs"},{"issue":"4","key":"1857_CR66","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3899\/jrheum.130905","volume":"41","author":"M Scarsi","year":"2014","unstructured":"Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41(4):666\u201372. https:\/\/doi.org\/10.3899\/jrheum.130905","journal-title":"J Rheumatol"},{"key":"1857_CR67","doi-asserted-by":"publisher","unstructured":"Correction. Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomized placebo-controlled phase IV study. RMD Open. 2019;5(2):e000813corr1. Published 2019 Dec 5. doi:https:\/\/doi.org\/10.1136\/rmdopen-2018-000813corr1","DOI":"10.1136\/rmdopen-2018-000813corr1"},{"issue":"7","key":"1857_CR68","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1002\/jcp.27860","volume":"234","author":"M Abbasi","year":"2019","unstructured":"Abbasi M, Mousavi MJ, Jamalzehi S, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;234(7):10018\u201331. https:\/\/doi.org\/10.1002\/jcp.27860","journal-title":"J Cell Physiol"},{"issue":"3","key":"1857_CR69","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14397595.2018.1481566","volume":"29","author":"T Mochizuki","year":"2019","unstructured":"Mochizuki T, Ikari K, Yano K, Sato M, Okazaki K. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Mod Rheumatol. 2019;29(3):413\u20137. https:\/\/doi.org\/10.1080\/14397595.2018.1481566","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1857_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","volume":"21","author":"G Ozen","year":"2019","unstructured":"Ozen G, Pedro S, Schumacher R, Simon TA, Michaud K. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Arthritis Res Ther. 2019;21(1):141. https:\/\/doi.org\/10.1186\/s13075-019-1921-z. Published 2019 Jun 7.","journal-title":"Arthritis Res Ther"},{"key":"1857_CR71","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","volume":"9","author":"K Hofmann","year":"2018","unstructured":"Hofmann K, Clauder AK, Manz RA. Targeting B cells and plasma cells in Autoimmune Diseases. Front Immunol. 2018;9:835. https:\/\/doi.org\/10.3389\/fimmu.2018.00835. Published 2018 Apr 23.","journal-title":"Front Immunol"},{"key":"1857_CR72","doi-asserted-by":"publisher","first-page":"108078","DOI":"10.1016\/j.intimp.2021.108078","volume":"99","author":"A Singh","year":"2021","unstructured":"Singh A, Behl T, Sehgal A, et al. Mechanistic insights into the role of B cells in rheumatoid arthritis. Int Immunopharmacol. 2021;99:108078. https:\/\/doi.org\/10.1016\/j.intimp.2021.108078","journal-title":"Int Immunopharmacol"},{"key":"1857_CR73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.imlet.2021.05.006","volume":"236","author":"E Bryl","year":"2021","unstructured":"Bryl E. B cells as target for immunotherapy in rheumatic diseases - current status. Immunol Lett. 2021;236:12\u20139. https:\/\/doi.org\/10.1016\/j.imlet.2021.05.006","journal-title":"Immunol Lett"},{"key":"1857_CR74","doi-asserted-by":"publisher","unstructured":"Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019;10.  Published 2019 Sep 6. https:\/\/doi.org\/10.3389\/fimmu.2019.01990","DOI":"10.3389\/fimmu.2019.01990"},{"issue":"1\u20132","key":"1857_CR75","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10354-014-0331-8","volume":"165","author":"E Rath","year":"2015","unstructured":"Rath E, Zwerina J, Oppl B, Nell-Duxneuner V. Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr. 2015;165(1\u20132):28\u201335. https:\/\/doi.org\/10.1007\/s10354-014-0331-8","journal-title":"Wien Med Wochenschr"},{"issue":"8","key":"1857_CR76","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/1756-185X.13596","volume":"22","author":"Y Shi","year":"2019","unstructured":"Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. Infection risks of rituximab versus nonrituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22(8):1361\u201370. https:\/\/doi.org\/10.1111\/1756-185X.13596","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"1857_CR77","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00296-019-04272-1","volume":"39","author":"J Vikse","year":"2019","unstructured":"Vikse J, Jonsdottir K, Kval\u00f8y JT, Wildhagen K, Omdal R. Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. Rheumatol Int. 2019;39(6):1083\u201390. https:\/\/doi.org\/10.1007\/s00296-019-04272-1","journal-title":"Rheumatol Int"},{"issue":"5","key":"1857_CR78","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/1756-185X.13511","volume":"22","author":"KC Wang","year":"2019","unstructured":"Wang KC, Liao HT, Chen WS, et al. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: a single-center experience in Taiwan. Int J Rheum Dis. 2019;22(5):860\u20138. https:\/\/doi.org\/10.1111\/1756-185X.13511","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"1857_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jconrel.2013.07.012","volume":"171","author":"YS Jung","year":"2013","unstructured":"Jung YS, Park W, Na K. Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis. J Control Release. 2013;171(2):143\u201351. https:\/\/doi.org\/10.1016\/j.jconrel.2013.07.012","journal-title":"J Control Release"},{"issue":"5","key":"1857_CR80","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/pharmaceutics11050235","volume":"11","author":"J Cao","year":"2019","unstructured":"Cao J, Zhang N, Wang Z, et al. Microneedle-Assisted transdermal delivery of Etanercept for Rheumatoid Arthritis Treatment. Pharmaceutics. 2019;11(5):235. https:\/\/doi.org\/10.3390\/pharmaceutics11050235. Published 2019 May 15.","journal-title":"Pharmaceutics"},{"key":"1857_CR81","doi-asserted-by":"publisher","unstructured":"Giulbudagian M, Yealland G, H\u00f6nzke S et al. Breaking the Barrier - Potent Anti-Inflammatory Activity following Efficient Topical Delivery of Etanercept using Thermoresponsive Nanogels. Theranostics. 2018;8(2):450\u2013463. Published 2018 Jan 1. doi:https:\/\/doi.org\/10.7150\/thno.21668","DOI":"10.7150\/thno.21668"},{"issue":"4","key":"1857_CR82","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0885328214535958","volume":"29","author":"\u00d6 Erdemli","year":"2014","unstructured":"Erdemli \u00d6, \u00d6zen S, Keskin D, et al. In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. J Biomater Appl. 2014;29(4):524\u201342. https:\/\/doi.org\/10.1177\/0885328214535958","journal-title":"J Biomater Appl"},{"issue":"41","key":"1857_CR83","doi-asserted-by":"publisher","first-page":"e2102102","DOI":"10.1002\/smll.202102102","volume":"17","author":"K Shen","year":"2021","unstructured":"Shen K, Sun G, Chan L, et al. Anti-inflammatory nanotherapeutics by targeting Matrix Metalloproteinases for Immunotherapy of spinal cord Injury. Small. 2021;17(41):e2102102. https:\/\/doi.org\/10.1002\/smll.202102102","journal-title":"Small"},{"key":"1857_CR84","doi-asserted-by":"publisher","unstructured":"Campos Y, Fuentes G, Almirall A et al. The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue. Pharmaceutics. 2022;14(2):282. Published 2022 Jan 26. doi:https:\/\/doi.org\/10.3390\/pharmaceutics14020282","DOI":"10.3390\/pharmaceutics14020282"},{"key":"1857_CR85","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.colsurfb.2017.07.080","volume":"159","author":"M Ferreira","year":"2017","unstructured":"Ferreira M, Barreiros L, Segundo MA, et al. Topical codelivery of methotrexate and etanercept using lipid nanoparticles: a targeted approach for psoriasis management. Colloids Surf B Biointerfaces. 2017;159:23\u20139. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.07.080","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1857_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jcis.2019.04.047","volume":"549","author":"G Sun","year":"2019","unstructured":"Sun G, Yang S, Cai H, et al. Molybdenum disulfide nanoflowers mediated anti-inflammation macrophage modulation for spinal cord injury treatment. J Colloid Interface Sci. 2019;549:50\u201362. https:\/\/doi.org\/10.1016\/j.jcis.2019.04.047","journal-title":"J Colloid Interface Sci"},{"key":"1857_CR87","doi-asserted-by":"publisher","first-page":"120717","DOI":"10.1016\/j.ijpharm.2021.120717","volume":"604","author":"RM Pabari","year":"2021","unstructured":"Pabari RM, Tambuwala MM, Lajczak-McGinley N, et al. Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis - A preliminary study. Int J Pharm. 2021;604:120717. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120717","journal-title":"Int J Pharm"},{"issue":"23","key":"1857_CR88","doi-asserted-by":"publisher","first-page":"9101","DOI":"10.3390\/ijms21239101","volume":"21","author":"T Rodr\u00edguez-Prieto","year":"2020","unstructured":"Rodr\u00edguez-Prieto T, Hern\u00e1ndez-Breijo B, Ortega MA, G\u00f3mez R, S\u00e1nchez-Nieves J, Guijarro LG. Dendritic nanotheranostic for the delivery of Infliximab: a potential carrier in Rheumatoid Arthritis Therapy. Int J Mol Sci. 2020;21(23):9101. https:\/\/doi.org\/10.3390\/ijms21239101. Published 2020 Nov 30.","journal-title":"Int J Mol Sci"},{"key":"1857_CR89","doi-asserted-by":"publisher","first-page":"118556","DOI":"10.1016\/j.carbpol.2021.118556","volume":"273","author":"X Li","year":"2021","unstructured":"Li X, Yu M, Zhu Z, et al. Oral delivery of infliximab using nanoin-microparticles for the treatment of inflammatory bowel disease. Carbohydr Polym. 2021;273:118556. https:\/\/doi.org\/10.1016\/j.carbpol.2021.118556","journal-title":"Carbohydr Polym"},{"key":"1857_CR90","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.2147\/JPR.S283518","volume":"13","author":"W Chen","year":"2020","unstructured":"Chen W, Li Z, Wang Z, Gao H, Ding J, He Z. Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel alleviates Pain and protects cartilage in rheumatoid arthritis. J Pain Res. 2020;13:3315\u201329. https:\/\/doi.org\/10.2147\/JPR.S283518. Published 2020 Dec 7.","journal-title":"J Pain Res"},{"issue":"9","key":"1857_CR91","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.spinee.2015.04.026","volume":"15","author":"M Likhitpanichkul","year":"2015","unstructured":"Likhitpanichkul M, Kim Y, Torre OM, et al. Fibrin-genipin annulus fibrosus sealant as a delivery system for anti-TNF\u03b1 drug. Spine J. 2015;15(9):2045\u201354. https:\/\/doi.org\/10.1016\/j.spinee.2015.04.026","journal-title":"Spine J"},{"issue":"3","key":"1857_CR92","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5731\/pdajpst.2013.00919","volume":"67","author":"KS Gokhale","year":"2013","unstructured":"Gokhale KS, Jonnalagadda S. Preparation and evaluation of sustained release infliximab microspheres. PDA J Pharm Sci Technol. 2013;67(3):255\u201366. https:\/\/doi.org\/10.5731\/pdajpst.2013.00919","journal-title":"PDA J Pharm Sci Technol"},{"key":"1857_CR93","doi-asserted-by":"publisher","unstructured":"Kim JM, Kim DH, Park HJ et al. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J Nanobiotechnology. 2020;18(1):133. Published 2020 Sep 15. doi:https:\/\/doi.org\/10.1186\/s12951-020-00693-4","DOI":"10.1186\/s12951-020-00693-4"},{"issue":"12","key":"1857_CR94","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/bjophthalmol-2016-310044","volume":"101","author":"R Zhang","year":"2017","unstructured":"Zhang R, Qian J, Li X, Yuan Y. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes. Br J Ophthalmol. 2017;101(12):1731\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-310044","journal-title":"Br J Ophthalmol"},{"issue":"23","key":"1857_CR95","doi-asserted-by":"publisher","first-page":"10808","DOI":"10.7150\/thno.47601","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang X, Yan J, Wang L, et al. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics. 2020;10(23):10808\u201322. https:\/\/doi.org\/10.7150\/thno.47601. Published 2020 Aug 29.","journal-title":"Theranostics"},{"key":"1857_CR96","doi-asserted-by":"publisher","unstructured":"Ries M, Moulari B, Shetab Boushehri MA et al. Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Pharmaceutics. 2022;14(2):352. Published 2022 Feb 2. doi:https:\/\/doi.org\/10.3390\/pharmaceutics14020352","DOI":"10.3390\/pharmaceutics14020352"},{"issue":"1","key":"1857_CR97","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/nano.2007.2.1.3","volume":"2","author":"T Barnes","year":"2007","unstructured":"Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Int J Nanomedicine. 2007;2(1):3\u20137. https:\/\/doi.org\/10.2147\/nano.2007.2.1.3","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"1857_CR98","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/mt.2008.99","volume":"16","author":"JC Fernandes","year":"2008","unstructured":"Fernandes JC, Wang H, Jreyssaty C, et al. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol Ther. 2008;16(7):1243\u201351. https:\/\/doi.org\/10.1038\/mt.2008.99","journal-title":"Mol Ther"},{"key":"1857_CR99","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejpb.2019.02.011","volume":"137","author":"J Cao","year":"2019","unstructured":"Cao J, Cheng J, Xi S, Qi X, Shen S, Ge Y. Alginate\/chitosan microcapsules for in situ delivery of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model. Eur J Pharm Biopharm. 2019;137:112\u201321. https:\/\/doi.org\/10.1016\/j.ejpb.2019.02.011","journal-title":"Eur J Pharm Biopharm"},{"issue":"30","key":"1857_CR100","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1016\/j.biomaterials.2012.06.101","volume":"33","author":"RE Whitmire","year":"2012","unstructured":"Whitmire RE, Wilson DS, Singh A, Levenston ME, Murthy N, Garc\u00eda AJ. Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins. Biomaterials. 2012;33(30):7665\u201375. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.06.101","journal-title":"Biomaterials"},{"key":"1857_CR101","doi-asserted-by":"publisher","first-page":"111171","DOI":"10.1016\/j.biopha.2020.111171","volume":"134","author":"B Ren","year":"2021","unstructured":"Ren B, Lu J, Li M, et al. Anti-inflammatory effect of IL-1ra-loaded dextran\/PLGA microspheres on Porphyromonas gingivalis lipopolysaccharide-stimulated macrophages in vitro and in vivo in a rat model of periodontitis. Biomed Pharmacother. 2021;134:111171. https:\/\/doi.org\/10.1016\/j.biopha.2020.111171","journal-title":"Biomed Pharmacother"},{"key":"1857_CR102","doi-asserted-by":"publisher","unstructured":"Liu M, Huang Y, Hu L et al. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol. 2012;12:68. Published 2012 Sep 25. doi:https:\/\/doi.org\/10.1186\/1472-6750-12-68","DOI":"10.1186\/1472-6750-12-68"},{"issue":"16","key":"1857_CR103","doi-asserted-by":"publisher","first-page":"e1800263","DOI":"10.1002\/adhm.201800263","volume":"7","author":"AEB Clements","year":"2018","unstructured":"Clements AEB, Groves ER, Chamberlain CS, Vanderby R, Murphy WL. Microparticles locally deliver active Interleukin-1 receptor antagonist in vivo. Adv Healthc Mater. 2018;7(16):e1800263. https:\/\/doi.org\/10.1002\/adhm.201800263","journal-title":"Adv Healthc Mater"},{"issue":"5","key":"1857_CR104","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1021\/nn500685h","volume":"8","author":"H Lee","year":"2014","unstructured":"Lee H, Lee MY, Bhang SH, et al. Hyaluronate-gold nanoparticle\/tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano. 2014;8(5):4790\u20138. https:\/\/doi.org\/10.1021\/nn500685h","journal-title":"ACS Nano"},{"issue":"8","key":"1857_CR105","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1039\/c7bm00254h","volume":"5","author":"Q Wang","year":"2017","unstructured":"Wang Q, Sun X. Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci. 2017;5(8):1407\u201320. https:\/\/doi.org\/10.1039\/c7bm00254h","journal-title":"Biomater Sci"},{"issue":"2","key":"1857_CR106","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jconrel.2012.06.030","volume":"162","author":"G Bisker","year":"2012","unstructured":"Bisker G, Yeheskely Hayon D, Minai L, Yelin D. Controlled release of Rituximab from gold nanoparticles for phototherapy of malignant cells. J Control Release. 2012;162(2):303\u20139. https:\/\/doi.org\/10.1016\/j.jconrel.2012.06.030","journal-title":"J Control Release"},{"issue":"2","key":"1857_CR107","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1021\/acs.biomac.0c01514","volume":"22","author":"Y Kim","year":"2021","unstructured":"Kim Y, Youn YS, Oh KT, Kim D, Lee ES. Tumor-targeting liposomes with transient holes allowing Intact Rituximab internally. Biomacromolecules. 2021;22(2):723\u201331. https:\/\/doi.org\/10.1021\/acs.biomac.0c01514","journal-title":"Biomacromolecules"},{"issue":"4","key":"1857_CR108","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/cbdd.12551","volume":"86","author":"H Li","year":"2015","unstructured":"Li H, Guo K, Wu C, et al. Controlled and targeted drug delivery by a UV-responsive Liposome for overcoming chemo-resistance in Non-Hodgkin Lymphoma. Chem Biol Drug Des. 2015;86(4):783\u201394. https:\/\/doi.org\/10.1111\/cbdd.12551","journal-title":"Chem Biol Drug Des"},{"key":"1857_CR109","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.colsurfb.2017.11.003","volume":"161","author":"S Saesoo","year":"2018","unstructured":"Saesoo S, Sathornsumetee S, Anekwiang P, et al. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma. Colloids Surf B Biointerfaces. 2018;161:497\u2013507. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.11.003","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"5","key":"1857_CR110","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/cbdd.13010","volume":"90","author":"H Yin","year":"2017","unstructured":"Yin H, Meng T, Shu L, et al. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-hodgkin\u2019s lymphoma. Chem Biol Drug Des. 2017;90(5):892\u20139. https:\/\/doi.org\/10.1111\/cbdd.13010","journal-title":"Chem Biol Drug Des"},{"issue":"10","key":"1857_CR111","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/1061186X.2018.1433680","volume":"26","author":"X Feng","year":"2018","unstructured":"Feng X, Chen Y. Drug delivery targets and systems for targeted treatment of rheumatoid arthritis. J Drug Target. 2018;26(10):845\u201357. https:\/\/doi.org\/10.1080\/1061186X.2018.1433680","journal-title":"J Drug Target"},{"issue":"4","key":"1857_CR112","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1166\/jnn.2019.15764","volume":"19","author":"L Zeng","year":"2019","unstructured":"Zeng L, Geng H, Gu W, et al. Au nanoparticles attenuate RANKL-Induced Osteoclastogenesis by suppressing Pre-Osteoclast Fusion. J Nanosci Nanotechnol. 2019;19(4):2166\u201373. https:\/\/doi.org\/10.1166\/jnn.2019.15764","journal-title":"J Nanosci Nanotechnol"},{"issue":"sup2","key":"1857_CR113","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/21691401.2018.1460373","volume":"46","author":"S Pirmardvand Chegini","year":"2018","unstructured":"Pirmardvand Chegini S, Varshosaz J, Taymouri S. Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment. Artif Cells Nanomed Biotechnol. 2018;46(sup2):502\u201314. https:\/\/doi.org\/10.1080\/21691401.2018.1460373","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"9","key":"1857_CR114","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/biom11091289","volume":"11","author":"K Koushki","year":"2021","unstructured":"Koushki K, Keshavarz Shahbaz S, Keshavarz M, Bezsonov EE, Sathyapalan T, Sahebkar A. Gold nanoparticles: multifaceted roles in the management of Autoimmune Disorders. Biomolecules. 2021;11(9):1289. https:\/\/doi.org\/10.3390\/biom11091289. Published 2021 Aug 30.","journal-title":"Biomolecules"},{"issue":"10","key":"1857_CR115","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/1440-1681.13531","volume":"48","author":"SM Shahen","year":"2021","unstructured":"Shahen SM, Mohamed MR, Ali MRK, Samaka RM, Hamdy GM, Talaat RM. Therapeutic potential of targeted-gold nanospheres on collagen-induced arthritis in rats. Clin Exp Pharmacol Physiol. 2021;48(10):1346\u201357. https:\/\/doi.org\/10.1111\/1440-1681.13531","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"17","key":"1857_CR116","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/cbic.201800201","volume":"19","author":"P Zhao","year":"2018","unstructured":"Zhao P, Wang Y, Wu A, Rao Y, Huang Y. Roles of albumin-binding proteins in Cancer Progression and Biomimetic targeted drug delivery. ChemBioChem. 2018;19(17):1796\u2013805. https:\/\/doi.org\/10.1002\/cbic.201800201","journal-title":"ChemBioChem"},{"key":"1857_CR117","doi-asserted-by":"publisher","unstructured":"Zhong J, Zhang Q, Zhang Z et al. Albumin mediated reactive oxygen species scavenging and targeted delivery of methotrexate for rheumatoid arthritis therapy.Nano Research.2021,15(1):153\u2013161. doi:https:\/\/doi.org\/10.1007\/s12274-021-3449-1","DOI":"10.1007\/s12274-021-3449-1"},{"issue":"5","key":"1857_CR118","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1021\/acsnano.9b01710","volume":"13","author":"L Liu","year":"2019","unstructured":"Liu L, Hu F, Wang H, et al. Secreted protein acidic and rich in cysteine mediated Biomimetic Delivery of Methotrexate by Albumin-Based nanomedicines for rheumatoid arthritis therapy. ACS Nano. 2019;13(5):5036\u201348. https:\/\/doi.org\/10.1021\/acsnano.9b01710","journal-title":"ACS Nano"},{"issue":"1","key":"1857_CR119","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/10717544.2022.2057616","volume":"29","author":"X Zheng","year":"2022","unstructured":"Zheng X, Yu X, Wang C, et al. Targeted codelivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy. Drug Deliv. 2022;29(1):1025\u201337. https:\/\/doi.org\/10.1080\/10717544.2022.2057616","journal-title":"Drug Deliv"},{"key":"1857_CR120","doi-asserted-by":"publisher","first-page":"9113","DOI":"10.2147\/IJN.S219413","volume":"14","author":"F Yan","year":"2019","unstructured":"Yan F, Li H, Zhong Z, et al. Co-Delivery of Prednisolone and Curcumin in Human serum albumin nanoparticles for effective treatment of rheumatoid arthritis. Int J Nanomedicine. 2019;14:9113\u201325. https:\/\/doi.org\/10.2147\/IJN.S219413. Published 2019 Nov 22.","journal-title":"Int J Nanomedicine"},{"issue":"12","key":"1857_CR121","doi-asserted-by":"publisher","first-page":"20424","DOI":"10.3390\/molecules191220424","volume":"19","author":"N Martinho","year":"2014","unstructured":"Martinho N, Florindo H, Silva L, Brocchini S, Zloh M, Barata T. Molecular modeling to study dendrimers for Biomedical Applications. Molecules. 2014;19(12):20424\u201367. https:\/\/doi.org\/10.3390\/molecules191220424. Published 2014 Dec 8.","journal-title":"Molecules"},{"key":"1857_CR122","doi-asserted-by":"publisher","first-page":"111845","DOI":"10.1016\/j.msec.2020.111845","volume":"121","author":"IM Oliveira","year":"2021","unstructured":"Oliveira IM, Gon\u00e7alves C, Oliveira EP, et al. PAMAM dendrimers functionalised with an anti-TNF \u03b1 antibody and chondroitin sulphate for treatment of rheumatoid arthritis. Mater Sci Eng C Mater Biol Appl. 2021;121:111845. https:\/\/doi.org\/10.1016\/j.msec.2020.111845","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"1857_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2019.05.018","volume":"92","author":"S Hajebi","year":"2019","unstructured":"Hajebi S, Rabiee N, Bagherzadeh M, et al. Stimulus-responsive polymeric nanogels as smart drug delivery systems. Acta Biomater. 2019;92:1\u201318. https:\/\/doi.org\/10.1016\/j.actbio.2019.05.018","journal-title":"Acta Biomater"},{"key":"1857_CR124","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejpb.2020.10.009","volume":"157","author":"NK Preman","year":"2020","unstructured":"Preman NK, Barki RR, Vijayan A, Sanjeeva SG, Johnson RP. Recent developments in stimuli-responsive polymer nanogels for drug delivery and diagnostics: a review. Eur J Pharm Biopharm. 2020;157:121\u201353. https:\/\/doi.org\/10.1016\/j.ejpb.2020.10.009","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"1857_CR125","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijpharm.2010.08.011","volume":"401","author":"NA Samah","year":"2010","unstructured":"Samah NA, Williams N, Heard CM. Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across skin. Int J Pharm. 2010;401(1\u20132):72\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.08.011","journal-title":"Int J Pharm"},{"issue":"8","key":"1857_CR126","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1039\/c7bm00254h","volume":"5","author":"Q Wang","year":"2017","unstructured":"Wang Q, Sun X. Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci. 2017;5(8):1407\u201320. https:\/\/doi.org\/10.1039\/c7bm00254h","journal-title":"Biomater Sci"},{"key":"1857_CR127","doi-asserted-by":"publisher","unstructured":"Nguyen Dung HT, Nguyen Ngoc B, Nguyen Linh TP et al. An Agarose\u2013Curdlan Nanogel that Carries Etanercept to Target and Neutralizes TNF-\u03b1 Produced by Dectin-1-Expressing Immune Cells. J Elec Mater. 2019;48(10):6570\u20136582. https:\/\/doi.org\/10.1007\/s11664-019-07458-2","DOI":"10.1007\/s11664-019-07458-2"},{"issue":"4","key":"1857_CR128","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1021\/nl504829f","volume":"15","author":"L Walsh","year":"2015","unstructured":"Walsh L, Ryu J, Bock S, et al. Nanotopography facilitates in vivo transdermal delivery of high molecular weight therapeutics through an integrin-dependent mechanism. Nano Lett. 2015;15(4):2434\u201341. https:\/\/doi.org\/10.1021\/nl504829f","journal-title":"Nano Lett"},{"issue":"1","key":"1857_CR129","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1021\/acsnano.1c07556","volume":"16","author":"HH Yu","year":"2022","unstructured":"Yu HH, Fan JL, Shehla NZ, et al. Biomimetic Hybrid membrane-coated Xuetongsu assisted with laser irradiation for efficient rheumatoid arthritis therapy. ACS Nano. 2022;16(1):502\u201321. https:\/\/doi.org\/10.1021\/acsnano.1c07556","journal-title":"ACS Nano"},{"issue":"10","key":"1857_CR130","doi-asserted-by":"publisher","first-page":"17062","DOI":"10.1021\/acsnano.2c07338","volume":"16","author":"S Qiu","year":"2022","unstructured":"Qiu S, Wu XN, Li Z, et al. A Smart Nanoreactor based on an O2-Economized Dual Energy Inhibition Strategy Armed with Dual Multistimuli-Responsive \u201cDoorkeepers\u201d for enhanced CDT\/PTT of Rheumatoid Arthritis. ACS Nano. 2022;16(10):17062\u201379. https:\/\/doi.org\/10.1021\/acsnano.2c07338","journal-title":"ACS Nano"},{"issue":"11","key":"1857_CR131","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11095-018-2478-2","volume":"35","author":"S Pandey","year":"2018","unstructured":"Pandey S, Kumar V, Leekha A, et al. Co-Delivery of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the treatment of rheumatoid arthritis: in Vitro characterization, pharmacodynamic and biochemical investigations. Pharm Res. 2018;35(11):201. https:\/\/doi.org\/10.1007\/s11095-018-2478-2","journal-title":"Pharm Res"},{"issue":"1","key":"1857_CR132","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"JY Choe","year":"2017","unstructured":"Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomized, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):58\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207764","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1857_CR133","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, et al. A phase III randomized, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207588","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1857_CR134","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1857_CR135","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5863\/1551-6776-27.1.63","volume":"27","author":"MC Trotta","year":"2022","unstructured":"Trotta MC, Alfano R, Cuomo G, et al. Comparison of timing to develop anti-drug antibodies to Infliximab and Adalimumab between Adult and Pediatric Age Groups, Males and Females. J Pediatr Pharmacol Ther. 2022;27(1):63\u201371. https:\/\/doi.org\/10.5863\/1551-6776-27.1.63","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"1857_CR136","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1080\/21645515.2020.1836919","volume":"17","author":"AT Melo","year":"2021","unstructured":"Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): where we stand today. Hum Vaccin Immunother. 2021;17(6):1586\u201398. https:\/\/doi.org\/10.1080\/21645515.2020.1836919","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1857_CR137","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of Autoimmune Diseases. A systematic review and Meta-analysis. BioDrugs. 2015;29(4):241\u201358. https:\/\/doi.org\/10.1007\/s40259-015-0134-5","journal-title":"BioDrugs"},{"key":"1857_CR138","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fimmu.2018.00230","volume":"9","author":"TK Kishimoto","year":"2018","unstructured":"Kishimoto TK, Maldonado RA. Nanoparticles for the induction of Antigen-Specific Immunological Tolerance. Front Immunol. 2018;9:230. https:\/\/doi.org\/10.3389\/fimmu.2018.00230. Published 2018 Feb 20.","journal-title":"Front Immunol"},{"issue":"23","key":"1857_CR139","doi-asserted-by":"publisher","first-page":"6642","DOI":"10.1039\/d2bm01348g","volume":"10","author":"SY Chen","year":"2022","unstructured":"Chen SY, Xu XX, Li X, et al. Recent advances in the intracellular delivery of macromolecule therapeutics. Biomater Sci. 2022;10(23):6642\u201355. https:\/\/doi.org\/10.1039\/d2bm01348g. Published 2022 Nov 22.","journal-title":"Biomater Sci"},{"key":"1857_CR140","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2019.08.004","volume":"144","author":"S Patel","year":"2019","unstructured":"Patel S, Kim J, Herrera M, Mukherjee A, Kabanov AV, Sahay G. Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev. 2019;144:90\u2013111. https:\/\/doi.org\/10.1016\/j.addr.2019.08.004","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"1857_CR141","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40257-015-0131-y","volume":"16","author":"ME Farhangian","year":"2015","unstructured":"Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285\u201394. https:\/\/doi.org\/10.1007\/s40257-015-0131-y","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"1857_CR142","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Positive breast Cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"issue":"1","key":"1857_CR143","doi-asserted-by":"publisher","first-page":"132","DOI":"10.18433\/jpps30583","volume":"23","author":"Z Eskandari","year":"2020","unstructured":"Eskandari Z, Bahadori F, Celik B, Onyuksel H. Targeted Nanomedicines for Cancer Therapy, from basics to clinical trials. J Pharm Pharm Sci. 2020;23(1):132\u201357. https:\/\/doi.org\/10.18433\/jpps30583","journal-title":"J Pharm Pharm Sci"},{"issue":"9","key":"1857_CR144","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00262-018-2207-z","volume":"67","author":"T Gargett","year":"2018","unstructured":"Gargett T, Abbas MN, Rolan P, et al. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Cancer Immunol Immunother. 2018;67(9):1461\u201372. https:\/\/doi.org\/10.1007\/s00262-018-2207-z","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"1857_CR145","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/17425247.2019.1662785","volume":"16","author":"S Sikder","year":"2019","unstructured":"Sikder S, Gote V, Alshamrani M, Sicotte J, Pal D. Long-term delivery of protein and peptide therapeutics for cancer therapies. Expert Opin Drug Deliv. 2019;16(10):1113\u201331. https:\/\/doi.org\/10.1080\/17425247.2019.1662785","journal-title":"Expert Opin Drug Deliv"},{"issue":"14","key":"1857_CR146","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.3390\/nano12142476","volume":"12","author":"RD Mellor","year":"2022","unstructured":"Mellor RD, Uchegbu IF. Ultrasmall-in-Nano: why size matters. Nanomaterials (Basel). 2022;12(14):2476. https:\/\/doi.org\/10.3390\/nano12142476. Published 2022 Jul 19.","journal-title":"Nanomaterials (Basel)"},{"issue":"9\u201310","key":"1857_CR147","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/smll.201201390","volume":"9","author":"X Duan","year":"2013","unstructured":"Duan X, Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small. 2013;9(9\u201310):1521\u201332. https:\/\/doi.org\/10.1002\/smll.201201390","journal-title":"Small"},{"issue":"3","key":"1857_CR148","doi-asserted-by":"publisher","first-page":"2000041","DOI":"10.1002\/anbr.202000041","volume":"1","author":"CJ Genito","year":"2021","unstructured":"Genito CJ, Batty CJ, Bachelder EM, Ainslie KM. Considerations for size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the development of Polymeric particle vaccines for infectious Diseases. Adv Nanobiomed Res. 2021;1(3):2000041. https:\/\/doi.org\/10.1002\/anbr.202000041","journal-title":"Adv Nanobiomed Res"},{"issue":"9","key":"1857_CR149","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cplu.202000496","volume":"85","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang G, Jin S, Xu L, Zhao CX. Development of high-drug-loading nanoparticles. ChemPlusChem. 2020;85(9):2143\u201357. https:\/\/doi.org\/10.1002\/cplu.202000496","journal-title":"ChemPlusChem"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01857-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T23:07:04Z","timestamp":1679699224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01857-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,25]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01857-8","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,25]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"105"}}